IBDEI1XN ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,30873,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30873,1,3,0)
;;=3^Acute nephritic syndrome w/ other morphologic changes
;;^UTILITY(U,$J,358.3,30873,1,4,0)
;;=4^N00.8
;;^UTILITY(U,$J,358.3,30873,2)
;;=^5015499
;;^UTILITY(U,$J,358.3,30874,0)
;;=N00.9^^123^1597^10
;;^UTILITY(U,$J,358.3,30874,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30874,1,3,0)
;;=3^Acute nephritic syndrome w/ unsp morphologic changes
;;^UTILITY(U,$J,358.3,30874,1,4,0)
;;=4^N00.9
;;^UTILITY(U,$J,358.3,30874,2)
;;=^5015500
;;^UTILITY(U,$J,358.3,30875,0)
;;=N01.0^^123^1597^69
;;^UTILITY(U,$J,358.3,30875,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30875,1,3,0)
;;=3^Rapidly progr neph synd w/ minor glomerular abnlt
;;^UTILITY(U,$J,358.3,30875,1,4,0)
;;=4^N01.0
;;^UTILITY(U,$J,358.3,30875,2)
;;=^5015501
;;^UTILITY(U,$J,358.3,30876,0)
;;=N01.1^^123^1597^68
;;^UTILITY(U,$J,358.3,30876,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30876,1,3,0)
;;=3^Rapidly progr neph synd w/ focal & seg glomerular lesions
;;^UTILITY(U,$J,358.3,30876,1,4,0)
;;=4^N01.1
;;^UTILITY(U,$J,358.3,30876,2)
;;=^5015502
;;^UTILITY(U,$J,358.3,30877,0)
;;=N01.2^^123^1597^66
;;^UTILITY(U,$J,358.3,30877,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30877,1,3,0)
;;=3^Rapidly progr neph synd w/ diffuse membranous glomrlneph
;;^UTILITY(U,$J,358.3,30877,1,4,0)
;;=4^N01.2
;;^UTILITY(U,$J,358.3,30877,2)
;;=^5015503
;;^UTILITY(U,$J,358.3,30878,0)
;;=N01.3^^123^1597^64
;;^UTILITY(U,$J,358.3,30878,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30878,1,3,0)
;;=3^Rapidly progr neph synd w/ diffus mesangial prolif glomrlneph
;;^UTILITY(U,$J,358.3,30878,1,4,0)
;;=4^N01.3
;;^UTILITY(U,$J,358.3,30878,2)
;;=^5015504
;;^UTILITY(U,$J,358.3,30879,0)
;;=N01.4^^123^1597^63
;;^UTILITY(U,$J,358.3,30879,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30879,1,3,0)
;;=3^Rapidly progr neph synd w/ diffus endocaplry prolif glomrlneph
;;^UTILITY(U,$J,358.3,30879,1,4,0)
;;=4^N01.4
;;^UTILITY(U,$J,358.3,30879,2)
;;=^5015505
;;^UTILITY(U,$J,358.3,30880,0)
;;=N01.5^^123^1597^67
;;^UTILITY(U,$J,358.3,30880,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30880,1,3,0)
;;=3^Rapidly progr neph synd w/ diffuse mesangiocap glomrlneph
;;^UTILITY(U,$J,358.3,30880,1,4,0)
;;=4^N01.5
;;^UTILITY(U,$J,358.3,30880,2)
;;=^5015506
;;^UTILITY(U,$J,358.3,30881,0)
;;=N01.6^^123^1597^62
;;^UTILITY(U,$J,358.3,30881,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30881,1,3,0)
;;=3^Rapidly progr neph synd w/ dense deposit disease
;;^UTILITY(U,$J,358.3,30881,1,4,0)
;;=4^N01.6
;;^UTILITY(U,$J,358.3,30881,2)
;;=^5015507
;;^UTILITY(U,$J,358.3,30882,0)
;;=N01.7^^123^1597^65
;;^UTILITY(U,$J,358.3,30882,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30882,1,3,0)
;;=3^Rapidly progr neph synd w/ diffuse crescentic glomrlneph
;;^UTILITY(U,$J,358.3,30882,1,4,0)
;;=4^N01.7
;;^UTILITY(U,$J,358.3,30882,2)
;;=^5015508
;;^UTILITY(U,$J,358.3,30883,0)
;;=N01.8^^123^1597^70
;;^UTILITY(U,$J,358.3,30883,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30883,1,3,0)
;;=3^Rapidly progr neph synd w/ oth morphologic changes
;;^UTILITY(U,$J,358.3,30883,1,4,0)
;;=4^N01.8
;;^UTILITY(U,$J,358.3,30883,2)
;;=^5015509
;;^UTILITY(U,$J,358.3,30884,0)
;;=N01.9^^123^1597^71
;;^UTILITY(U,$J,358.3,30884,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30884,1,3,0)
;;=3^Rapidly progr neph synd w/ unsp morphologic changes
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1XN 3790 printed Sep 23, 2025@19:53:49 Page 2
IBDEI1XN ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,30873,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,30873,1,3,0)
+4 ;;=3^Acute nephritic syndrome w/ other morphologic changes
+5 ;;^UTILITY(U,$J,358.3,30873,1,4,0)
+6 ;;=4^N00.8
+7 ;;^UTILITY(U,$J,358.3,30873,2)
+8 ;;=^5015499
+9 ;;^UTILITY(U,$J,358.3,30874,0)
+10 ;;=N00.9^^123^1597^10
+11 ;;^UTILITY(U,$J,358.3,30874,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,30874,1,3,0)
+14 ;;=3^Acute nephritic syndrome w/ unsp morphologic changes
+15 ;;^UTILITY(U,$J,358.3,30874,1,4,0)
+16 ;;=4^N00.9
+17 ;;^UTILITY(U,$J,358.3,30874,2)
+18 ;;=^5015500
+19 ;;^UTILITY(U,$J,358.3,30875,0)
+20 ;;=N01.0^^123^1597^69
+21 ;;^UTILITY(U,$J,358.3,30875,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,30875,1,3,0)
+24 ;;=3^Rapidly progr neph synd w/ minor glomerular abnlt
+25 ;;^UTILITY(U,$J,358.3,30875,1,4,0)
+26 ;;=4^N01.0
+27 ;;^UTILITY(U,$J,358.3,30875,2)
+28 ;;=^5015501
+29 ;;^UTILITY(U,$J,358.3,30876,0)
+30 ;;=N01.1^^123^1597^68
+31 ;;^UTILITY(U,$J,358.3,30876,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,30876,1,3,0)
+34 ;;=3^Rapidly progr neph synd w/ focal & seg glomerular lesions
+35 ;;^UTILITY(U,$J,358.3,30876,1,4,0)
+36 ;;=4^N01.1
+37 ;;^UTILITY(U,$J,358.3,30876,2)
+38 ;;=^5015502
+39 ;;^UTILITY(U,$J,358.3,30877,0)
+40 ;;=N01.2^^123^1597^66
+41 ;;^UTILITY(U,$J,358.3,30877,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,30877,1,3,0)
+44 ;;=3^Rapidly progr neph synd w/ diffuse membranous glomrlneph
+45 ;;^UTILITY(U,$J,358.3,30877,1,4,0)
+46 ;;=4^N01.2
+47 ;;^UTILITY(U,$J,358.3,30877,2)
+48 ;;=^5015503
+49 ;;^UTILITY(U,$J,358.3,30878,0)
+50 ;;=N01.3^^123^1597^64
+51 ;;^UTILITY(U,$J,358.3,30878,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,30878,1,3,0)
+54 ;;=3^Rapidly progr neph synd w/ diffus mesangial prolif glomrlneph
+55 ;;^UTILITY(U,$J,358.3,30878,1,4,0)
+56 ;;=4^N01.3
+57 ;;^UTILITY(U,$J,358.3,30878,2)
+58 ;;=^5015504
+59 ;;^UTILITY(U,$J,358.3,30879,0)
+60 ;;=N01.4^^123^1597^63
+61 ;;^UTILITY(U,$J,358.3,30879,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,30879,1,3,0)
+64 ;;=3^Rapidly progr neph synd w/ diffus endocaplry prolif glomrlneph
+65 ;;^UTILITY(U,$J,358.3,30879,1,4,0)
+66 ;;=4^N01.4
+67 ;;^UTILITY(U,$J,358.3,30879,2)
+68 ;;=^5015505
+69 ;;^UTILITY(U,$J,358.3,30880,0)
+70 ;;=N01.5^^123^1597^67
+71 ;;^UTILITY(U,$J,358.3,30880,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,30880,1,3,0)
+74 ;;=3^Rapidly progr neph synd w/ diffuse mesangiocap glomrlneph
+75 ;;^UTILITY(U,$J,358.3,30880,1,4,0)
+76 ;;=4^N01.5
+77 ;;^UTILITY(U,$J,358.3,30880,2)
+78 ;;=^5015506
+79 ;;^UTILITY(U,$J,358.3,30881,0)
+80 ;;=N01.6^^123^1597^62
+81 ;;^UTILITY(U,$J,358.3,30881,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,30881,1,3,0)
+84 ;;=3^Rapidly progr neph synd w/ dense deposit disease
+85 ;;^UTILITY(U,$J,358.3,30881,1,4,0)
+86 ;;=4^N01.6
+87 ;;^UTILITY(U,$J,358.3,30881,2)
+88 ;;=^5015507
+89 ;;^UTILITY(U,$J,358.3,30882,0)
+90 ;;=N01.7^^123^1597^65
+91 ;;^UTILITY(U,$J,358.3,30882,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,30882,1,3,0)
+94 ;;=3^Rapidly progr neph synd w/ diffuse crescentic glomrlneph
+95 ;;^UTILITY(U,$J,358.3,30882,1,4,0)
+96 ;;=4^N01.7
+97 ;;^UTILITY(U,$J,358.3,30882,2)
+98 ;;=^5015508
+99 ;;^UTILITY(U,$J,358.3,30883,0)
+100 ;;=N01.8^^123^1597^70
+101 ;;^UTILITY(U,$J,358.3,30883,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,30883,1,3,0)
+104 ;;=3^Rapidly progr neph synd w/ oth morphologic changes
+105 ;;^UTILITY(U,$J,358.3,30883,1,4,0)
+106 ;;=4^N01.8
+107 ;;^UTILITY(U,$J,358.3,30883,2)
+108 ;;=^5015509
+109 ;;^UTILITY(U,$J,358.3,30884,0)
+110 ;;=N01.9^^123^1597^71
+111 ;;^UTILITY(U,$J,358.3,30884,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,30884,1,3,0)
+114 ;;=3^Rapidly progr neph synd w/ unsp morphologic changes
